Multifunctional Theranostic Red Blood Cells For Magnetic‐Field‐Enhanced in vivo Combination Therapy of Cancer

Wang, Chao; Sun, Xiaoqi; Cheng, Liang; Yin, Shengnan; Yang, Guangbao; Li, Yonggang; Liu, Zhuang

doi:10.1002/adma.201400158

Cited by 226 publications

(155 citation statements)

References 38 publications

(41 reference statements)

Supporting

Mentioning

151

Contrasting

Order By: Relevance

“…83 However, for further clinical applications of this approach, it is also necessary to evaluate the long-term toxicity of these decoy particles, in addition to all other concerns related to safety of the IONPs. As an alternative approach, Wang et al 84 labeled red blood cells with IONPs and observed a significantly longer blood circulation time and efficient tumor targeting after intravenous administration of these cells.…”

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

et al. 2015

View full text Add to dashboard Cite

Iron oxide nanoparticles (IONPs) have been extensively used during the last two decades, either as effective bio-imaging contrast agents or as carriers of biomolecules such as drugs, nucleic acids and peptides for controlled delivery to specific organs and tissues. Most of these novel applications require elaborate tuning of the physiochemical and surface properties of the IONPs. As new IONPs designs are envisioned, synergistic consideration of the body's innate biological barriers against the administered nanoparticles and the short and long-term side effects of the IONPs become even more essential. There are several important criteria (e.g. size and size-distribution, charge, coating molecules, and plasma protein adsorption) that can be effectively tuned to control the in vivo pharmacokinetics and biodistribution of the IONPs. This paper reviews these crucial parameters, in light of biological barriers in the body, and the latest IONPs design strategies used to overcome them. A careful review of the long-term biodistribution and side effects of the IONPs in relation to nanoparticle design is also given. While the discussions presented in this review are specific to IONPs, some of the information can be readily applied to other nanoparticle systems, such as gold, silver, silica, calcium phosphates and various polymers.

show abstract

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, the elevation of ROS around tumor environment can selectively kill cancer cells. Photodynamic therapy has been successfully used in skin diseases in the clinic and further extended to cancers 30-33. ROS produced by photosensitizers can be used in photodynamic therapy and to cleave thioketal groups to release drugs.…”

Section: Introductionmentioning

confidence: 99%

ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source

et al. 2016

View full text Add to dashboard Cite

Mitochondria in cancer cells maintain a more negative membrane potential than normal cells. Mitochondria are the primary source of cellular reactive oxygen species (ROS), which are necessary for photodynamic therapy. Thus, the strategy of targeting mitochondria can maximize the photodynamic therapeutic efficiency for cancer. Here we report, for the first time, synthesis of a new mitochondria-targeting drug delivery system, ZnPc/CPT-TPPNPs. To synthesize this novel compound, polyethylene glycol was functionalized with thioketal linker-modified camptothecin (TL-CPT) and triphenylphosphonium to form the block copolymer, TL-CPT-PEG1K-TPP. The ZnPc/CPT-TPPNPs was constructed for delivery of the photosensitizer Zinc phthalocyanine (ZnPc) by blending the block copolymer TL-CPT-PEG1K-TPP with 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DSPE-PEG).Triphenylphosphine can accumulate selectively several hundred-fold within mitochondria. The thioketal linker is ROS-responsive and CPT can be released upon ROS cleavage. We also show that the ZnPc loaded in ZnPc/CPT-TPPNPs absorbed the 633 nm laser to produce ROS, which could be utilized both in photodynamic therapy and to cleave the thioketal linker thereby releasing camptothecin for chemotherapy. Thus, the mitochondria-targeting nanoparticles could elevate photodynamic therapeutic efficacy. Our results showed that surface modification of the nanoparticles with triphenylphosphine cations facilitated efficient subcellular delivery of the photosensitizer to mitochondria. The nanoparticles had a good ROS-responsive effect to release CPT, which could transfer to the nucleus and interfere with DNA replication as a topoisomeraseⅠinhibitor. Thus, the blended nanoparticles provide a new promising approach as a mitochondria-targeting ROS-activated chemo- and photodynamic therapy with a single light source for lung cancer.

show abstract

“…With appropriate targeting ligands and surface modifications, an enhanced accumulation of IONPs in tumor tissues by passive or active targeting has been shown in animal tumor models while significantly reducing nonspecific accumulation in the liver and spleen [29,30]. Moreover, the unique magnetic properties of IONPs offer strong MRI contrast enhancing effect for MRI to monitor of drug delivery, evaluate treatment responses and external magnetic-field-controlled drug release or hyperthermia treatment [31]. Therefore, IONP is an excellent candidate for the development of new tumor imaging, targeted drug delivery and image-guided therapy that have the potential for novel clinical applications.…”

mentioning

confidence: 99%

Magnetic Nanoparticles for Precision Oncology: Theranostic Magnetic Iron Oxide Nanoparticles for Image-Guided and Targeted Cancer Therapy

Zhu

Zhou

Mao

et al. 2016

Nanomedicine (Lond.)

237

147

View full text Add to dashboard Cite

Recent advances in the development of magnetic nanoparticles (MNPs) have shown promise in the development of new personalized therapeutic approaches for clinical management of cancer patients. The unique physicochemical properties of MNPs endow them with novel multifunctional capabilities for imaging, drug delivery and therapy, which are referred to as theranostics. To facilitate the translation of those theranostic MNPs into clinical applications, extensive efforts have been made on designing and improving biocompatibility, stability, safety, drug-loading ability, targeted delivery, imaging signal and thermal-or photodynamic response. In this review, we provide an overview of the physicochemical properties, toxicity and theranostic applications of MNPs with a focus on magnetic iron oxide nanoparticles.

show abstract

Multifunctional Theranostic Red Blood Cells For Magnetic‐Field‐Enhanced in vivo Combination Therapy of Cancer

Cited by 226 publications

References 38 publications

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source

Magnetic Nanoparticles for Precision Oncology: Theranostic Magnetic Iron Oxide Nanoparticles for Image-Guided and Targeted Cancer Therapy

Contact Info

Product

Resources

About